Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1

Gnanapragasam Arunachalam, Samson Mathews Samuel, Isra Marei, Hong Ding, Christopher Triggle

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background and Purpose Endothelial dysfunction can be detected at an early stage in the development of diabetes-related microvascular disease and is associated with accelerated endothelial senescence and ageing. Hyperglycaemia-induced oxidative stress is a major contributing factor to the development of endothelial dysfunction. Clinical data indicate that the hypoglycaemic agent, metformin, has an endothelial protective action; however, its molecular and cellular mechanisms remain elusive. In the present study, we have investigated the protective effect of metformin during hyperglycaemia- induced senescence in mouse microvascular endothelial cells (MMECs). Experimental Approach MMECs were cultured in normal glucose (11 mM) and high glucose (HG; 40 mM) in the presence and absence of metformin (50 μM) for 72 h. The expression of sirtuin-1 (SIRT1) and senescence/apoptosis-associated markers was determined by immunoblotting and immunocyto techniques. SIRT1 expression was inhibited with appropriate siRNA. Key Results Exposure of MMECs to HG significantly reduced SIRT1 protein expression, increased forkhead box O1 (FoxO-1) and p53 acetylation, increased p21 and decreased Bcl2 expression. In addition, senescence-associated β-galactosidase activity in MMECs was increased in HG. Treatment with metformin attenuated the HG-induced reduction of SIRT1 expression, modulated the SIRT1 downstream targets FoxO-1 and p53/p21, and protected endothelial cells from HG-induced premature senescence. However, following gene knockdown of SIRT1 the effects of metformin were lost. Conclusions and Implications HG-induced down-regulation of SIRT1 played a crucial role in diabetes-induced endothelial senescence. Furthermore, the protective effect of metformin against HG-induced endothelial dysfunction was partly due to its effects on SIRT1 expression and/or activity.

Original languageEnglish
Pages (from-to)523-535
Number of pages13
JournalBritish Journal of Pharmacology
Volume171
Issue number2
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Sirtuin 1
Metformin
Hyperglycemia
Apoptosis
Endothelial Cells
Galactosidases
Gene Knockdown Techniques
Glucose
Acetylation
Immunoblotting
Hypoglycemic Agents
Small Interfering RNA
Oxidative Stress
Down-Regulation

Keywords

  • endothelial dysfunction
  • forkhead box O1 transcription factor
  • FoxO-1
  • hyperglycaemia
  • metformin
  • microvascular endothelial cells
  • reactive oxygen species
  • sirtuin1
  • vascular senescence

ASJC Scopus subject areas

  • Pharmacology

Cite this

Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. / Arunachalam, Gnanapragasam; Mathews Samuel, Samson; Marei, Isra; Ding, Hong; Triggle, Christopher.

In: British Journal of Pharmacology, Vol. 171, No. 2, 01.01.2014, p. 523-535.

Research output: Contribution to journalArticle

@article{f2b3399f1dc843d290ce0a27b8b80761,
title = "Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1",
abstract = "Background and Purpose Endothelial dysfunction can be detected at an early stage in the development of diabetes-related microvascular disease and is associated with accelerated endothelial senescence and ageing. Hyperglycaemia-induced oxidative stress is a major contributing factor to the development of endothelial dysfunction. Clinical data indicate that the hypoglycaemic agent, metformin, has an endothelial protective action; however, its molecular and cellular mechanisms remain elusive. In the present study, we have investigated the protective effect of metformin during hyperglycaemia- induced senescence in mouse microvascular endothelial cells (MMECs). Experimental Approach MMECs were cultured in normal glucose (11 mM) and high glucose (HG; 40 mM) in the presence and absence of metformin (50 μM) for 72 h. The expression of sirtuin-1 (SIRT1) and senescence/apoptosis-associated markers was determined by immunoblotting and immunocyto techniques. SIRT1 expression was inhibited with appropriate siRNA. Key Results Exposure of MMECs to HG significantly reduced SIRT1 protein expression, increased forkhead box O1 (FoxO-1) and p53 acetylation, increased p21 and decreased Bcl2 expression. In addition, senescence-associated β-galactosidase activity in MMECs was increased in HG. Treatment with metformin attenuated the HG-induced reduction of SIRT1 expression, modulated the SIRT1 downstream targets FoxO-1 and p53/p21, and protected endothelial cells from HG-induced premature senescence. However, following gene knockdown of SIRT1 the effects of metformin were lost. Conclusions and Implications HG-induced down-regulation of SIRT1 played a crucial role in diabetes-induced endothelial senescence. Furthermore, the protective effect of metformin against HG-induced endothelial dysfunction was partly due to its effects on SIRT1 expression and/or activity.",
keywords = "endothelial dysfunction, forkhead box O1 transcription factor, FoxO-1, hyperglycaemia, metformin, microvascular endothelial cells, reactive oxygen species, sirtuin1, vascular senescence",
author = "Gnanapragasam Arunachalam and {Mathews Samuel}, Samson and Isra Marei and Hong Ding and Christopher Triggle",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/bph.12496",
language = "English",
volume = "171",
pages = "523--535",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1

AU - Arunachalam, Gnanapragasam

AU - Mathews Samuel, Samson

AU - Marei, Isra

AU - Ding, Hong

AU - Triggle, Christopher

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background and Purpose Endothelial dysfunction can be detected at an early stage in the development of diabetes-related microvascular disease and is associated with accelerated endothelial senescence and ageing. Hyperglycaemia-induced oxidative stress is a major contributing factor to the development of endothelial dysfunction. Clinical data indicate that the hypoglycaemic agent, metformin, has an endothelial protective action; however, its molecular and cellular mechanisms remain elusive. In the present study, we have investigated the protective effect of metformin during hyperglycaemia- induced senescence in mouse microvascular endothelial cells (MMECs). Experimental Approach MMECs were cultured in normal glucose (11 mM) and high glucose (HG; 40 mM) in the presence and absence of metformin (50 μM) for 72 h. The expression of sirtuin-1 (SIRT1) and senescence/apoptosis-associated markers was determined by immunoblotting and immunocyto techniques. SIRT1 expression was inhibited with appropriate siRNA. Key Results Exposure of MMECs to HG significantly reduced SIRT1 protein expression, increased forkhead box O1 (FoxO-1) and p53 acetylation, increased p21 and decreased Bcl2 expression. In addition, senescence-associated β-galactosidase activity in MMECs was increased in HG. Treatment with metformin attenuated the HG-induced reduction of SIRT1 expression, modulated the SIRT1 downstream targets FoxO-1 and p53/p21, and protected endothelial cells from HG-induced premature senescence. However, following gene knockdown of SIRT1 the effects of metformin were lost. Conclusions and Implications HG-induced down-regulation of SIRT1 played a crucial role in diabetes-induced endothelial senescence. Furthermore, the protective effect of metformin against HG-induced endothelial dysfunction was partly due to its effects on SIRT1 expression and/or activity.

AB - Background and Purpose Endothelial dysfunction can be detected at an early stage in the development of diabetes-related microvascular disease and is associated with accelerated endothelial senescence and ageing. Hyperglycaemia-induced oxidative stress is a major contributing factor to the development of endothelial dysfunction. Clinical data indicate that the hypoglycaemic agent, metformin, has an endothelial protective action; however, its molecular and cellular mechanisms remain elusive. In the present study, we have investigated the protective effect of metformin during hyperglycaemia- induced senescence in mouse microvascular endothelial cells (MMECs). Experimental Approach MMECs were cultured in normal glucose (11 mM) and high glucose (HG; 40 mM) in the presence and absence of metformin (50 μM) for 72 h. The expression of sirtuin-1 (SIRT1) and senescence/apoptosis-associated markers was determined by immunoblotting and immunocyto techniques. SIRT1 expression was inhibited with appropriate siRNA. Key Results Exposure of MMECs to HG significantly reduced SIRT1 protein expression, increased forkhead box O1 (FoxO-1) and p53 acetylation, increased p21 and decreased Bcl2 expression. In addition, senescence-associated β-galactosidase activity in MMECs was increased in HG. Treatment with metformin attenuated the HG-induced reduction of SIRT1 expression, modulated the SIRT1 downstream targets FoxO-1 and p53/p21, and protected endothelial cells from HG-induced premature senescence. However, following gene knockdown of SIRT1 the effects of metformin were lost. Conclusions and Implications HG-induced down-regulation of SIRT1 played a crucial role in diabetes-induced endothelial senescence. Furthermore, the protective effect of metformin against HG-induced endothelial dysfunction was partly due to its effects on SIRT1 expression and/or activity.

KW - endothelial dysfunction

KW - forkhead box O1 transcription factor

KW - FoxO-1

KW - hyperglycaemia

KW - metformin

KW - microvascular endothelial cells

KW - reactive oxygen species

KW - sirtuin1

KW - vascular senescence

UR - http://www.scopus.com/inward/record.url?scp=84891275812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891275812&partnerID=8YFLogxK

U2 - 10.1111/bph.12496

DO - 10.1111/bph.12496

M3 - Article

C2 - 24372553

AN - SCOPUS:84891275812

VL - 171

SP - 523

EP - 535

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -